SomnoMed Limited Overview
SomnoMed is the self-described global market leader in custom oral appliance therapy (OAT) for obstructive sleep apnea (OSA), snoring and sleep bruxism. It designs, manufactures and sells prescription mandibular advancement devices under the SomnoDent family and related brands (Flex, Fusion, Classic, Avant, Herbst Advance Elite, and the new Virtus). Dentists fit the devices on referral from sleep physicians, in a reimbursed medical-device channel. The company has treated more than one million patients, which it says is a first for any OAT company. About 95% of revenue is earned outside Australia: Europe accounts for about 54%, North America about 40%, and APAC the remainder. After a 2023–24 manufacturing crisis and two dilutive recapitalisations, SomnoMed rebuilt capacity, returned to positive EBITDA (A$10.9m in FY26) and eliminated its debt. Its differentiating technology bet is Rest Assure, the first oral appliance with FDA-cleared in-built compliance monitoring. Its near-term challenge is restoring growth after a weak second half of FY26 in Europe, a CEO consolidation and a share price down about 55–60% in 2026.
Company's own description
SomnoMed describes itself in ASX releases as "a public company providing treatment solutions for sleep-related breathing disorders including obstructive sleep apnea, snoring and bruxism." In its FY26 investor presentation (August 2026) it states its vision as "a world where our oral appliance therapy is the standard of care for obstructive sleep apnea treatment." Its mission statement positions it as "the global leader in oral appliance therapy" that sets the standard for outcomes, innovation and patient experience. The Annual Report 2025 describes the group as producing and selling devices for the oral treatment of sleep-related disorders in Asia Pacific, North America and Europe.
Independent characterisation
SomnoMed is a vertically integrated, mid-sized dental medical-device manufacturer. Its products are custom, patient-specific Class II (US) medical devices. Each device is made to order from a dentist's impression or intra-oral scan, produced in SomnoMed's own manufacturing facilities using CAD/CAM, milling and finishing, and shipped back to the dentist for fitting.
The economic engine is a per-device unit sale. The FY26 MAS device gross margin was 71.5%, and group gross margin was 61.1% after lower-margin ancillary and distributed items. Demand is driven by a referral chain: patient → physician or sleep test → diagnosis → prescription → dentist → SomnoMed lab. Reimbursement by Medicare, private insurers and European statutory insurers strongly shapes volume.
Business model and revenue mix
| Revenue stream | Description | Disclosure |
|---|---|---|
| Custom oral appliances (MAS) | SomnoDent family, HAE, Virtus; sold per unit to dentists, clinics and distributors | The large majority of revenue; exact % not separately disclosed |
| Ancillary products | Cleaning tablets (SOMTabs, proprietary), accessories, replacement and refurbishment | — |
| Health Care Company (HIC) revenue – Netherlands | Revenue associated with Dutch "Health Care Companies" channel arrangements | Separately called out in FY23 Europe commentary ("excluding HIC") |
| Connected care / software (future) | Rest Assure compliance-monitoring device plus app/docking station; potential recurring data or service revenue | Pre-commercial; commercialisation expected FY27 (1H FY26 commentary) |
| Subscription / licensing | None material disclosed | — |
Mix assessment: Effectively about 100% product revenue today. There is no material service, subscription or licensing income. Rest Assure is the only route to a technology-enabled or recurring component.
Value-chain position
SomnoMed sits at the device design and manufacturing node and controls distribution through direct sales forces in key markets. It does not diagnose OSA; that is done by sleep labs, physicians and home sleep tests. It also does not fit devices; that is done by dentists. Its customers are dentists (it cites a potential customer pool of 700,000+ dentists in key regions). The end-users are patients, and the payers are insurers and governments. Upstream inputs are dental polymers and metals, milling equipment and 3D printing consumables.
Customer types and end-markets
| Customer / end-market | Role |
|---|---|
| General and sleep-specialised dentists | Direct purchasers; fit and titrate devices |
| Sleep physicians, ENTs, GPs | Referral sources (prescribers) |
| Health insurers and statutory payers (e.g., US Medicare via CMS codes; European statutory insurers) | Reimbursement gatekeepers |
| Patients (self-pay in non-reimbursed markets such as parts of APAC) | End-users; price-sensitive when out-of-pocket |
| Dutch Health Care Companies (HIC) | Channel partners in the Netherlands |
| Pharma (GLP-1 manufacturers) | Emerging collaborators. The company reports "continued engagement with GLP-1 manufacturer" (FY26 presentation). |
Strategy
Stated strategy themes (FY26 Results Presentation, August 2026)
Management frames FY24–FY26 as "Financial & Operational Turnaround". In that phase it cleared debt, generated positive cash flow, invested in talent and increased capacity to improve turnaround times. It frames FY27–FY30 as "Growth & Profitability Objectives":
-
Return to double-digit revenue growth.
-
Progressively expand EBITDA margins through scale and efficiency gains.
-
Organic growth focus, with consideration of small-scale acquisition opportunities.
The three-pillar growth plan ("A Bold Vision to Drive Growth FY27 & Beyond"):
-
Capture the growing patient pool. Targets GLP-1 and other pharma-led diagnosis trends, connected care and home diagnostics, and CPAP failures (up to 50% of CPAP patients discontinue).
-
Accelerate new products aligned to market needs. Virtus now; Connected Care / Rest Assure next.
-
Expand referring and treating clinicians. Clinician connectivity and engagement, and an expanded reimbursement framework.
A detailed strategic roadmap is to be presented at the 23 November 2026 AGM.
Initiatives announced in the last 24 months
| Initiative | Date | Detail | Status |
|---|---|---|---|
| Manufacturing capacity expansion | FY25–FY26 | Capacity +50% (FY25), +20% (FY26); production times down more than 50%; further site expansion planned | Ongoing; capex A$5.7m in FY26 |
| Rest Assure clinical and regulatory program | FY25–FY27 | FDA 510(k) for compliance cleared October 2024; pre-submission and US clinical study protocol to support a treated-AHI efficacy 510(k) (AGM November 2025) | Commercialisation expected FY27 (1H FY26 commentary) |
| Virtus launch | July 2026 | Global controlled market release for OSA plus bruxism | Broad adoption assumed from 2H FY27 |
| Leadership build-out | February 2026 | New Chief Marketing Officer and Chief Transformation Officer roles | CTO promoted to COO, July 2026 |
| CEO consolidation | 27 July 2026 | Move from co-CEO to sole CEO (Karen Borg) | Complete |
| Board renewal | 16 October 2026 | Russo retires; Price becomes Chair | Effective at AGM, 23 November 2026 |
| Europe recovery plan | July–August 2026 | Targeted actions after reimbursement and referral changes; dedicated product strategies; reimbursement improvement application in a key market | In progress |
| North America CMS strategy | FY26–FY27 | Product innovation aimed at the most accessible CMS (Medicare) codes; cohort-specific demand generation | In progress |
| GLP-1 engagement | FY26 | "Continued engagement with GLP-1 manufacturer" | Nature of relationship not disclosed |
| APAC reset | FY26–FY27 | Restructured leadership; product line extensions for non-reimbursed markets under investigation | In progress |
| Free-float improvement | September 2025 | A$11.25m block trade (16.07m shares at A$0.70) to diversify the register | Complete |
| Cost restructuring ("tranche 3") | FY26 | One-off cost of A$0.7m | Complete |
Guidance and medium-term targets
| Period | Guidance | Outcome |
|---|---|---|
| FY24 (initial) | Revenue growth ≥12%; capex A$5m | Cut April 2024 to 6–9% growth and EBITDA of –A$1m to A$0m; actual +9.6%, EBITDA A$0.6m |
| FY25 (initial, August 2024) | Revenue about A$100m; EBITDA >A$5m; capex A$3–4m | Raised to about A$105m in February 2025; actual A$111.5m and EBITDA A$9.2m (beat) |
| FY26 (August 2025) | Revenue A$119–126m; EBITDA A$10–12m; capex A$6–8m | Revenue A$114.5m (miss); EBITDA A$10.9m (in range); capex A$5.7m (below) |
| FY27 (July / August 2026) | High-single-digit revenue growth; EBITDA margin consistent with FY26 (about 9.6%). The formal range is to be issued at the AGM on 23 November 2026. | Pending |
| FY27–FY30 | Return to double-digit growth; progressive EBITDA margin expansion | Aspirational; no numeric target |
Key FY27 assumptions stated: continued North America growth and EU stabilisation, global Virtus adoption in 2H FY27, stable margins while investing, and FX.
ESG and sustainability commitments: None quantified in the retrieved materials.
Products & Services
All devices are custom-made, prescription mandibular advancement splints or devices (MAS/MAD). They hold the airway open by positioning the lower jaw forward, which the company calls Continuous Open Airway Therapy (COAT). Pricing to dentists is not publicly disclosed for any product.
FY26 strategic portfolio framing (FY26 presentation, "A Bold Vision to Drive Growth FY27 & Beyond"):
Existing: HAE, Classic, Flex, Fusion
New: Virtus
Future: Connected Care / Rest Assure
- Product line extensions for non-reimbursed environments are under investigation.
Product Portfolio
| Product | Segment focus | Description and key capabilities | Target patient | Launch / status | Notes |
|---|---|---|---|---|---|
SomnoDent Classic | Global | The original twin-block style SomnoDent MAS; adjustable advancement | Mild-to-moderate OSA, snoring | Original platform (2004 lineage) | Listed among "existing" products in the FY26 roadmap |
SomnoDent Flex | NAM-led, global | Twin-block MAS with flexible/soft-lined design for comfort; built to satisfy US reimbursement criteria | OSA patients in reimbursed US channel | Established | FY26 presentation: "Designed for US Reimbursement / Medicare Reimbursed" |
SomnoDent Fusion | NAM-led, global | Hybrid hard/soft construction MAS; Medicare-reimbursable design | OSA, Medicare beneficiaries | Established | Grouped with Flex in the FY26 portfolio slide |
SomnoDent Avant | NAM, Europe | Low-profile, minimal-bulk design aimed at comfort and adherence | Comfort-sensitive OSA patients | Launched mid/late 2010s | Did not obtain full US Medicare reimbursement in FY23; appeal pursued (Annual Report 2023) |
Herbst Advance Elite (HAE) | Europe | Herbst-mechanism (telescopic arm) MAS reimbursed across key European markets | OSA patients in European statutory systems | Established | FY26 presentation: "Established European Platforms / Reimbursed across Key European Markets" |
Virtus | Global | Next-generation oral appliance designed for patients with OSA plus coexisting sleep bruxism (teeth grinding/clenching), a cohort the company estimates at about 50% of OSA patients (citing Li et al., J Clin Sleep Med 2023, 914 adults) | OSA patients with bruxism | Global controlled market release commenced July 2026; broad adoption assumed from 2H FY27 | Management: strengthens position in an "underserved segment" |
Rest Assure | NAM first, then EU and APAC | First OAT with in-built sensor for objective, all-night compliance monitoring; docking station plus patient app; designed to enable large-scale real-world data and, potentially, direct-to-patient marketing | Patients and prescribers wanting objective adherence data (parity with CPAP data) | FDA 510(k) K233497 cleared 3 October 2024 (compliance monitoring only); efficacy (treated-AHI) claim to require a further 510(k) supported by a US clinical study; commercialisation expected FY27 | The company positions it as a premium product; "Connected Care / Rest Assure" is listed as "Future" in the FY26 roadmap |
SomnoDent with micro-recording | NAM | Earlier-generation SomnoDent with embedded third-party compliance micro-recorder | Prescribers needing compliance data | FDA 510(k) cleared in the mid-2010s | Precursor to the fully integrated Rest Assure |
SOMTabs | Global | Proprietary appliance cleaning tablets | All SomnoDent users | Established | Supply and manufacturing issues noted in Annual Report 2023 |
Sleep bruxism / snoring appliances | Global | Oral devices for bruxism and simple snoring | Non-OSA patients | Established | The company lists bruxism and snoring within its treatment scope |
Digital workflow (intra-oral scan intake, CAD/CAM) | Global | Fully digital SomnoDent manufacturing ("two fully digitally made SomnoDent" products, Annual Report 2022) | Dentists using intra-oral scanners | 2022 onward | Enabler of capacity expansion (+40% over FY25–FY26) |
Financial Narrative
Income statement
Sources: FY22 revenue and EBITDA: FY22 results and Annual Report 2022. FY23: Annual Report 2023 (EBITDA A$2.1m; device GM 72%). FY24: FY26 presentation ("vs A$0.6m FY24") and Quartr (FY24 revenue A$91.7m, +9.6%). FY25–FY26: FY26 Results Presentation and Appendix 4E. FY23–FY25 NPAT and EPS: InvestSMART/Morningstar financial summary.
FY26 EPS is approximate (Investing.com TTM –A$0.012). Simply Wall St reports FY24 EPS as –A$0.10, versus –7.6c from InvestSMART. The discrepancy likely reflects weighted shares around the April–May 2024 rights issue. FY23 EBITDA is A$2.1m on the company definition, while InvestSMART shows A$0.7m on a different basis; the company figure is used.
Operating income (EBIT) is not reported as a statutory line in the retrieved materials. Craft reports 1H FY26 EBIT of A$2.8m.
Revenue CAGR FY22–FY26: (114.5 / 72.6)^(1/4) – 1 = 12.1% per year. The FY21–FY26 five-year CAGR, based on FY21 revenue of A$62.7m, is 12.8%.
Commentary. The five-year revenue line shows steady double-digit growth, except in FY24, when the manufacturing crisis capped shipments, and FY26, when Europe and FX weighed. The transformation is in profitability. EBITDA moved from roughly breakeven (FY22–FY24) to A$9–11m (FY25–FY26), driven by three factors:
-
Operating leverage on more than A$20m of incremental revenue in FY25.
-
Cost restructuring across three tranches of programs.
-
A recovery in gross margin to 61.1% as manufacturing yields improved.
Statutory losses persist for three reasons:
-
Share-based payments of A$3.6m in FY26, which are non-cash and higher year on year.
-
Unrealised FX of A$1.1m.
-
Tax of A$2.2m paid on profitable European and US subsidiaries, while Australian and corporate losses are not tax-effected.
FY26's 2H revenue decline (–7% reported, –1% constant currency) is the key inflection investors are now weighing.
Half-year profile
2H FY26 figures are derived as FY26 minus 1H FY26 and should be treated as derived, not reported. Sources: 1H FY24/1H FY25/1H FY26 half-year releases.
The seasonality is structural. 1H (July–December) benefits from patients claiming before calendar-year insurance resets, particularly in Europe and the US (company commentary, FY25 and FY26).
Balance sheet
Sources: FY25–FY26 from FY26 Results Presentation; FY22 cash from Annual Report 2022; FY24 cash from 1H FY25 release; equity and long-term debt FY23–FY25 from InvestSMART/Morningstar. At 31 December 2025, total assets were A$79.9m and equity A$50.0m (1H FY26 report).
Short/long debt split. The residual A$0.4m (FY26) is "European government-backed borrowings" (FY26 presentation). A short/long-term split was not disclosed in the summary.
Working capital (derived from listed items). Receivables plus inventory minus payables equals A$6.4m in FY25 and A$5.5m in FY26. The improvement came from better collections and lower prepayments and accruals.
Commentary. The balance sheet was rebuilt by two raises: A$15.5m gross in September 2023 at A$0.60 and A$22.6m gross in April–May 2024 at A$0.21. These lifted equity from A$24.5m (FY23) to A$45.9m (FY24) and allowed repayment of the drawn A$16m facility. Since FY24, the business has self-funded, and cash has held at about A$17m despite capex rising to A$5.7m. Intangibles (A$22.4m) consist mainly of capitalised development (Rest Assure, digital manufacturing) and legacy goodwill.
Cash flow
Notes: The FY23 raise was completed in September 2023, which falls in FY24 by settlement date. It is placed here at announcement (31 August 2023, the FY23 results day) and is in substance an FY24 inflow, alongside the A$22.6m April 2024 raise. In FY26, financing inflow included A$2.0m from the employee share trust repaying its loan on 2.86m shares sold in the September 2025 block trade. 1H FY24 operating cash flow was –A$4.6m. Source: FY26 Results Presentation cash flow summary.
Commentary. Cash conversion is good at the EBITDA line: operating cash flow before leases was 76% of EBITDA in FY26. Tax paid (A$1.4m) and one-off settlements (A$0.9m) consume part of it. Capex is the swing factor: FY26 guidance was A$6–8m, and A$5.7m was delivered. More than 50% of capex went to growth and manufacturing capacity, which pushed FCF slightly negative. Management's framing is that the business can fund capacity and R&D internally but has little surplus for large M&A.
Key ratios
Sources and derivations: ROE FY23–FY25 from InvestSMART/Morningstar. FY26 ROE is derived as –2.65 / 47.4. ROA, asset turnover, net debt/EBITDA and D/E are derived from disclosed FY25–FY26 balance-sheet and P&L items. FY26 interest was nil, so coverage is not meaningful. Including lease liabilities, gross debt to equity was 0.17x (FY25) and 0.11x (FY26).
The listed current items alone (cash, receivables and inventory of A$39.1m against payables and current tax of A$17.4m) imply comfortable liquidity of more than 2x.
ROIC: Negative on a statutory basis. On an underlying basis, EBITDA less D&A and leases gives about A$5m pre-tax on about A$30m of invested capital (equity less net cash), which is high-teens percent. This is analyst-derived, not company-reported.
Cash conversion cycle: Not publicly disclosed.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Income Statement and Margin Analysis (%)
| Metric | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
Revenue (AUD Mn) | 72.6 | 83.6 | 91.7 | 111.5 | 114.5 |
Revenue growth reported (%) | 16 | 15 | 9.6 | 21.6 | 2.7 |
Gross profit (AUD Mn) | — | — | — | 66.7 | 70.0 |
Group gross margin (%) | — | — | — | 59.9 | 61.1 |
MAS device gross margin (%) | 70 | 72 | — | 70.3 | 71.5 |
Underlying EBITDA (AUD Mn) | 1.3 | 2.1 | 0.6 | 9.2 | 10.9 |
EBITDA margin (%) | 1.8 | 2.5 | 0.7 | 8.2 | 9.6 |
Loss before tax (AUD Mn) | — | — | — | -0.8 | -0.5 |
Income tax expense (AUD Mn) | — | — | — | -2.7 | -2.2 |
Net profit after tax (AUD Mn) | — | -8.0 | -12.2 | -3.5 | -2.7 |
Net margin (%) | — | -9.6 | -13.3 | -3.1 | -2.3 |
EPS basic (A$ cents) | — | -7.4 | -7.6 | -1.6 | -1.2 |
Dividends per share (A$ cents) | 0 | 0 | 0 | 0 | 0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement
| Metric | 1H FY24 | 1H FY25 | 1H FY26 | 2H FY26 |
|---|---|---|---|---|
Revenue (AUD Mn) | 45.1 | 53.7 | 60.7 | 53.8 |
Underlying EBITDA (AUD Mn) | -1.1 | 5.8 | 7.8 | 3.1 |
NPAT (AUD Mn) | — | -0.1 | 0.8 | -3.4 |
Balance Sheet
| Metric | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
Total assets (AUD Mn) | — | — | — | 81.0 | 75.0 |
Cash and equivalents (AUD Mn) | 15.6 | — | 16.2 | 17.3 | 17.2 |
Trade and other receivables (AUD Mn) | — | — | — | 18.5 | 14.5 |
Inventories (AUD Mn) | — | — | — | 7.4 | 7.4 |
Property, plant and equipment (AUD Mn) | — | — | — | 7.0 | 7.6 |
Intangible assets incl. goodwill (AUD Mn) | — | — | — | 21.5 | 22.4 |
Right-of-use assets (AUD Mn) | — | — | — | 6.9 | 4.7 |
Trade and other payables (AUD Mn) | — | — | — | 19.5 | 16.4 |
Borrowings excl. leases (AUD Mn) | — | — | — | 0.8 | 0.4 |
Lease liabilities (AUD Mn) | — | — | — | 7.2 | 5.0 |
Total liabilities (AUD Mn) | — | — | — | 34.6 | 27.6 |
Net cash excl. leases (AUD Mn) | — | — | — | 16.5 | 16.8 |
Shareholders' equity (AUD Mn) | — | 24.5 | 45.9 | 46.4 | 47.4 |
Long-term debt incl. leases per Morningstar (AUD Mn) | — | 20.9 | 4.1 | 5.2 | — |
Cash Flow
| Metric | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
Underlying EBITDA (AUD Mn) | 1.3 | 2.1 | 0.6 | 9.2 | 10.9 |
Operating cash flow before leases (AUD Mn) | — | — | — | 7.8 | 8.3 |
Lease payments (AUD Mn) | — | — | — | -3.0 | -3.1 |
Operating cash flow after leases (AUD Mn) | — | — | — | 4.8 | 5.2 |
Capex – PP&E (AUD Mn) | — | — | — | -2.4 | -3.3 |
Capex – intangibles (AUD Mn) | — | — | — | -1.6 | -2.5 |
Total capex (AUD Mn) | — | — | — | -4.0 | -5.7 |
Free cash flow after leases (AUD Mn) | — | — | — | 0.8 | -0.6 |
Dividends paid (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Equity raised gross (AUD Mn) | 0 | 15.5 | 22.6 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
ROE (%) | -32.1 | -20.0 | -7.4 | -5.6 |
ROA (%) | — | — | -4.3 | -3.5 |
Return on capital per Morningstar (%) | -13 | -14 | -6 | — |
Debt (excl. leases) / equity (x) | — | — | 0.02 | 0.01 |
Net debt / EBITDA (x) | — | — | -1.8 | -1.5 |
Asset turnover (x) | — | — | 1.38 | 1.48 |
Interest coverage, EBITDA / interest (x) | — | — | 92 | — |
Region revenue (AUD Mn)
| Region revenue (AUD Mn) | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
Europe (FY23 ex-HIC) | 47.3 | — | 61 | 61.9 |
North America | 30.2 | — | 43 | 46 |
APAC (FY23 derived residual incl. HIC) | 6.1 | — | 7 | 7 |
Group | 83.6 | 91.7 | 111.5 | 114.5 |
Region growth reported (%)
| Region growth reported (%) | FY23 | FY25 | FY26 |
|---|---|---|---|
Europe | 12 | — | 1 |
North America | 22 | — | 7 |
APAC | — | — | -3 |
Group | 15 | 21.6 | 2.7 |
Share Price & Returns
| Reference point | Price (AUD) | Source |
|---|---|---|
30 June 2021 | 2.21 | Market Index |
30 June 2022 | 1.19 | Market Index |
30 June 2023 | 0.955 | Market Index |
2 May 2024 (all-time-low zone) | 0.20 | InvestSMART |
16 September 2025 (block trade) | 0.70 | ASX |
13 January 2026 | 0.725 | InvestSMART |
27 February 2026 (1H result) | 0.66 | InvestSMART |
27 July 2026 (pre-update) | 0.47 | InvestSMART |
31 August 2026 | 0.335 | FNArena |
1 October 2026 | 0.30 | Investing.com |
Share price at 30 June (AUD) | FY22 | FY23 |
SOM closing price (AUD) | 1.19 | 0.955 |
Total return (approximate, to about A$0.30, 1 October 2026)
| Total return (approximate, to about A$0.30, 1 October 2026) | Return |
|---|---|
1-year (from about A$0.70, October 2025) | about –57% |
3-year (from about A$0.45, October 2023) | about –33% |
5-year (from about A$2.30, October 2021) | about –87% |
Valuation Multiples
| Multiple | SomnoMed | Basis |
|---|---|---|
Market cap | about A$66m | Investing.com |
Enterprise value (excl. leases) | about A$49m | Market cap less net cash of A$16.8m |
EV / FY26 underlying EBITDA | about 4.5x | A$49m / A$10.9m |
EV / FY26 sales | about 0.43x | A$49m / A$114.5m |
P / book | about 1.4x | A$66m / A$47.4m |
P / E | n/m (loss) | — |
Peer context | ResMed and Inspire trade at materially higher EV/sales and EV/EBITDA (not quantified here; verify live) | — |
Analyst Ratings & Targets
| Broker | Rating | Target (AUD) | Date |
|---|---|---|---|
Morgans | Speculative Buy | 0.76 | 31 August 2026 |
Canaccord Genuity | Buy | 1.00 | — |
Consensus (Investing.com) | — | 0.837 average (range 0.76–0.99) | October 2026 |
Stockopedia consensus | — | 0.99 | — |
Analyst Conclusions
Management guidance
FY27: High-single-digit revenue growth, which implies about A$122–126m, with EBITDA margin consistent with FY26 (about 9.6%). That implies EBITDA of about A$11.7–12.1m on analyst arithmetic. The formal range is to be issued at the 23 November 2026 AGM, alongside a detailed strategic roadmap.
FY27–FY30: Return to double-digit revenue growth; progressive EBITDA margin expansion; organic focus with possible small acquisitions.
Consensus
Broker targets of A$0.76–1.00 imply that the market price embeds substantial scepticism, at a 60–70% discount to targets.
Bull case
-
The cash-generating core is mispriced. At about 4.5x EV/EBITDA and about 0.4x EV/sales, with A$16.8m net cash and 71.5% device gross margins, the market is valuing SomnoMed as if FY26's 2H decline were permanent. Delivering even the FY27 target (about A$12m EBITDA) re-rates the stock toward broker targets.
-
North America is a compounding growth engine. About 40% of revenue is growing about 11% in constant currency, CMS-code-targeted products are coming, and the GLP-1-expanded diagnosis funnel could support double-digit group growth once Europe stabilises.
-
Optionality from Rest Assure and Virtus. The only FDA-cleared compliance-monitoring OAT, launching in FY27, plus a device for the roughly 50% of OSA patients with bruxism, give SomnoMed differentiated, premium-priced products against low-cost labs.
Bear case
-
Growth has structurally decelerated. Group growth fell from 21.6% (FY25) to 2.7% (FY26), the 2H was negative, and Europe (54% of revenue) faces reimbursement and referral headwinds that management cannot control.
-
Execution and credibility risk. There have been two guidance misses or cuts in three years, a CEO structure change at the moment of a miss, a Chair departure within four months, and a newly promoted COO and CMO. Investor trust must be rebuilt before any re-rating.
-
Therapeutic substitution and price pressure. GLP-1s and future OSA drugs may shrink the severe-OSA pool, neurostimulation captures CPAP failures, and lower-cost OAT erodes pricing. Meanwhile, share-based payments (A$3.6m) and tax keep statutory earnings negative.
Catalysts and monitorables (next 12 months)
| Timing | Catalyst |
|---|---|
| 23 November 2026 | AGM: formal FY27 guidance range, strategic roadmap, Andrew Price takes the Chair, vote on Remuneration Report and option plans |
| 1H FY27 (December 2026 half) | Seasonally strongest period; evidence of European stabilisation and North America momentum |
| February 2027 | 1H FY27 results (TDM escrow already expired; watch for overhang) |
| 2H FY27 | Virtus broad global adoption (key guidance assumption) |
| FY27 | Rest Assure commercial launch; progress of the US clinical study toward a treated-AHI 510(k) |
| Ongoing | AUD/USD and AUD/EUR rates; European reimbursement decisions; any bolt-on M&A; substantial-holder movements (TDM 25%; June 2026 entrant) |
Analyst verdict
SomnoMed enters FY27 as a company whose operational repair is largely complete but whose growth story is unproven again. The FY24–FY26 turnaround was real and measurable:
-
Revenue rose from A$91.7m to A$114.5m.
-
Underlying EBITDA rose from A$0.6m to A$10.9m.
-
Manufacturing capacity grew about 40% and turnaround times halved.
-
Debt was eliminated, leaving A$16.8m of net cash.
Few small-cap medtech companies have rebuilt so thoroughly after a near-crisis that required raising equity at A$0.21 in 2024.
Yet the market has re-rated the shares down by more than half in 2026, for defensible reasons. The FY26 revenue miss came from SomnoMed's largest and most mature region, Europe, and stemmed from reimbursement and referral changes the company does not control. The guidance miss coincided with the departure of one co-CEO, the Chair is now leaving, and the FY27 target of high-single-digit growth is modest against a business that grew 22% a year earlier. Statutory losses persist, driven partly by share-based payments equal to a third of EBITDA, which governance-focused investors will scrutinise at the November AGM.
At about A$0.30, investors pay about A$49m of enterprise value for a global category leader generating about A$11m of underlying EBITDA. That price embeds little value for North American growth, Virtus or Rest Assure. The asymmetry is attractive, but the thesis now depends on near-term proof rather than vision:
-
Credible FY27 guidance at the AGM.
-
A stabilising European 1H FY27.
-
Visible Virtus uptake.
-
A dated, de-risked Rest Assure commercial launch.
Verdict: Speculative, value-supported recovery situation. The rating should be revisited after the November 2026 AGM guidance and the February 2027 half-year result, which together will show whether FY26's 2H was a pause or a new trend.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Background | Education / age |
|---|---|---|---|---|
Karen Borg | Chief Executive Officer and Executive Director | Director since 26 November 2020; Co-CEO from c. 2023; sole CEO since 27 July 2026 | Former CEO of Catholic Healthcare Ltd; CEO of Healthdirect; inaugural CEO of Jobs for NSW; senior roles in FTSE 100–250 medical device, technology and consumer companies; early career at Goodman Fielder, Nestlé and Revlon; board of KOPWA Aged Care Services; former Interim Chair of the Australian Vaccine Research Alliance | Not publicly disclosed in retrieved materials |
Ye-Fei Guo | Chief Financial Officer | — | Presented FY26 results | — |
Greg Knight | Chief Operating Officer | Promoted 27 July 2026 from Chief Transformation Officer (role created 1H FY26) | Oversees global manufacturing and operations | — |
Nathan Minnich | Chief Marketing Officer | Role created 1H FY26 | Leads global marketing | — |
Amrita Blickstead (former) | Co-CEO and Executive Director | Board c. 2020; executive about 3.5 years; departed 27 July 2026 | Led the turnaround with Borg. Held 2,392,364 shares, 1,885,000 options and 600,000 zero-exercise-price options at exit. | — |
Neil Verdal-Austin (former) | Managing Director/CEO | Led the company through FY22–FY23 | — | — |
“—” = not publicly disclosed.
Board of Directors
| Director | Role | Appointed | Independence | Notes |
|---|---|---|---|---|
Guy (Gaetano) Russo | Non-Executive Chair | Chair since August 2020 | Independent | Retiring at the 23 November 2026 AGM; bought 665,000 shares at A$0.443 in December 2024 |
Andrew Price | Non-Executive Director; Chair-elect | 17 January 2025 | Independent (presumed) | Standing for re-election in November 2026; to become Chair |
Benjamin Gisz | Non-Executive Director | 8 October 2024 | Not independent. Nominee of TDM Growth Partners, the largest shareholder | Director and investment team member at TDM; standing for re-election in November 2026 |
Karen Borg | CEO and Executive Director | 26 November 2020 | Executive | — |
Hamish Corlett (former) | NED (TDM nominee) | 1 May 2018 – 8 October 2024 | — | Replaced by Gisz |
Hilton Brett (former) | Director | Resigned 12 October 2023 | — | — |
Governance Timeline
| Date | Person | Instrument | Quantity | Stated value |
|---|---|---|---|---|
28 June 2024 | Karen Borg | Options issued | 750,000 | A$189,375 |
1 July 2024 | Karen Borg | Options issued | 575,000 | A$155,250 |
1 July 2025 | Karen Borg | Securities issued | 600,000 | A$384,000 |
6 August 2025 | Karen Borg | Options exercised | 750,000 | A$588,750 |
4 December 2025 | Karen Borg | Options issued (post-AGM) | 1,700,000 | A$1,360,000 |
4 December 2025 | Benjamin Gisz | Options issued | 200,000 | A$160,000 |
23 July 2026 | Karen Borg | Options exercised / shares acquired | 575,000 | A$270,250 |
Major Shareholders
| Holder | Shares | % (approx.) | Date / source |
|---|---|---|---|
TDM Growth Partners / TDM Asset Management and associates | 54,504,649 (plus 300,000 options) | 25.0 | After block trade, 16 September 2025 (FilingReader / ASX) |
Unnamed new substantial holder | — | ≥5 | — |
Karen Borg (CEO) | Not fully verified; includes 476,191 rights-issue shares (2024) plus option exercises | <2 | Director notices |
Guy Russo (Chair) | ≥665,000 | <1 | December 2024 notice |
Other top-10 holders | — | — | Annual Report 2026 top-20 list |
“—” = not publicly disclosed.
Competitive Landscape
Key Competitors
| Competitor | Segment overlap | Scale (latest, approx.) | Positioning vs SomnoMed |
|---|---|---|---|
ResMed (NYSE: RMD / ASX: RMD) – including the Narval CC oral appliance | CPAP (substitute) and OAT (direct) | — | Dominant OSA company; its CPAP is first-line, while OAT is a niche for ResMed |
Philips Respironics | CPAP (substitute) | Segment not separately comparable | Weakened after the 2021 recall and US consent decree; indirectly benefits OAT |
Fisher & Paykel Healthcare (NZX/ASX: FPH) | CPAP masks (substitute) | Revenue about NZ$2.0bn (FY25) – from memory | Mask leader; not an OAT maker |
Inspire Medical Systems (NYSE: INSP) | Hypoglossal nerve stimulation (substitute for CPAP-intolerant patients) | Revenue about US$800m (CY2024) – from memory | High-cost, surgical; competes for the same "CPAP failure" patient |
Eli Lilly – Zepbound (tirzepatide) | Pharmacotherapy (FDA-approved for OSA in obesity, December 2024) | n/m | Both threat and funnel: drives diagnosis, may reduce severity, and SomnoMed engages a GLP-1 maker |
Apnimed (AD109, private) | Investigational oral OSA drug | Pre-commercial | Potential long-term substitute |
Glidewell Laboratories (private, US) | OAT (EMA, Silent Nite, others) | — | Large US dental lab; price competitor |
ProSomnus (US; formerly Nasdaq: OSA) | Precision OAT (US) | Revenue about US$27–30m (2023) – from memory; restructured and taken private in 2024 | Direct US competitor in digitally manufactured OAT |
Panthera Dental (private, Canada) | CAD/CAM OAT (D-SAD, others) | — | Direct competitor in North America and Europe |
Vivos Therapeutics (Nasdaq: VVOS) | Oral appliances / airway (US) | Revenue about US$15m (2024) – from memory | Niche, differentiated "remodelling" claims |
Airway Management (private, US; TAP/myTAP) | OAT | — | US competitor |
OrthoApnea (Spain), Somnowell, Erkodent, local dental labs | OAT (Europe) | — | Lower-cost European competitors |
“—” = not publicly disclosed.
Peer Comparison FY2026
| Metric | SomnoMed (FY26) | ResMed (FY25) | Inspire (CY24) | ProSomnus (CY23) |
|---|---|---|---|---|
Revenue (local currency, millions) | A$114.5 | about US$5,100 | about US$800 | about US$28 |
Revenue growth (%) | 3 | about 10 | about 28 | — |
Gross margin (%) | 61.1 | about 59 | about 85 | — |
EBITDA / operating margin (%) | 9.6 (underlying EBITDA) | about 30+ (operating) | low single-digit (operating) | negative |
R&D intensity (%) | about 2 (capitalised only; total not disclosed) | about 6–7 | about 10+ | — |



